Evaluation of 90Y-DTPA and 90Y-DOTA for potential application in intra-vascular radionuclide therapy.
90Y-1,4,7,10-tetraazacyclododecane tetraacetic acid (90Y-DOTA) and 90Y-diethylene triamine pentaacetic acid (90Y-DTPA) complexes were studied for possible use in intra-vascular radionuclide therapy (IVRNT). 90Y was obtained from a 90Sr-90Y generator based on supported liquid membrane technique. The 90Y-DOTA and 90Y-DTPA complexes were prepared under optimised conditions. Bio-distribution of the complexes in Swiss mice showed that nearly 90% of 90Y complexes of both the ligands were excreted via urine within 1 h post-injection with negligible localisation in vital organs. Probenecid inhibition studies showed that both complexes are excreted by glomerular filtration. The predominant and quick excretion of 90Y-DOTA and 90Y-DTPA through the kidneys suggest that both these complexes could be explored for use in IVRNT.
Pandey
Usha
U
Radiopharmaceuticals Division, Isotope Group, Bhabha Atomic Research Centre, Mumbai 400 085, India.
Mukherjee
Archana
A
Sarma
H D
HD
Das
Tapas
T
Pillai
M R A
MR
Venkatesh
Meera
M
D015906:Angioplasty, Balloon, Coronary; D000818:Animals; D001918:Brachytherapy; D003331:Coronary Vessels / Q000528:radiation effects; D006573:Heterocyclic Compounds, 1-Ring / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D007668:Kidney / Q000378:metabolism; D051379:Mice; D004369:Pentetic Acid / Q000493:pharmacokinetics / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D015607:Stents; D014018:Tissue Distribution; D015021:Yttrium Radioisotopes / Q000493:pharmacokinetics* / Q000627:therapeutic use*
D006573:Heterocyclic Compounds, 1-Ring; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes; C071349:1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid; D004369:Pentetic Acid